Allos Pharma
Targeting the biology of autism — not just the symptoms.
Allos Pharma is advancing arbaclofen as a potential disease-modifying treatment for Fragile X syndrome and autism spectrum disorder.
The Science
A potential disease-modifying treatment.
Recent discoveries show that the many causes of autism converge on shared pathophysiological processes — an elevated excitation/inhibition ratio and altered neuronal protein synthesis. Arbaclofen corrects this biology.
Validated across animal models
Corrects core ASD phenotypes in 10+ genetic and environmental models.
Rescues human biomarkers
Normalizes EEG, ERG, and binocular rivalry signals in patients.
Meaningful clinical improvements
Replicated benefits in social function across independent ASD trials.
Excellent safety profile
Well-tolerated in children, adolescents, and adults; long-term OLE data.
Our Story
25 years of pioneering a new approach to autism.
Allos Pharma's founders, Mark Bear, PhD, and Randall Carpenter, MD, pioneered the strategy of targeting the underlying molecular pathophysiology of autism — rather than its symptoms. Their foundational science helped define an entire field.
- 2001Foundational mGluR5–FXS discoveries
- 2005Seaside Therapeutics founded
- 2012Phase 3 trials in FXS advanced
- 2020Allos secures exclusive FXS license
- 2025Allos acquires global rights to arbaclofen
Partnership
Let's bring arbaclofen to the patients and families who need it.
Partner with Allos to accelerate the first disease-modifying treatment for ASD and Fragile X Syndrome.